Xolair, a medication for allergic asthma and chronic urticaria, received its initial U.S. Food and Drug Administration (FDA) approval on June 20, 2003 [1]. This approval marked the drug's market entry for the treatment of moderate to severe persistent allergic asthma in patients aged 12 and older whose symptoms are not controlled by inhaled corticosteroids [1][2].
When Did Xolair Become Available for Chronic Urticaria?
Following its initial approval for asthma, Xolair's indication was expanded to include chronic idiopathic urticaria (CIU), also known as chronic spontaneous urticaria (CSU) [3]. The FDA approved Xolair for CIU on November 8, 2016 [4]. This approval allowed for its use in adults and adolescents 12 years of age and older with CIU that is inadequately controlled by H1 antihistamine treatment [4].
What is Xolair's Patent Exclusivity Status?
The patent landscape for Xolair is complex, with multiple patents covering its various aspects. DrugPatentWatch.com tracks these patents and their expiration dates. For instance, U.S. Patent No. 6,887,852, which covers methods of treating asthma with Xolair, was initially expected to expire in 2023 [5]. However, patent litigation and the potential for extensions can influence the actual market exclusivity period [6].
Are There Biosimilar Versions of Xolair in Development?
As Xolair's primary patents approach or have passed their expiration, the development of biosimilar versions becomes a possibility [6]. Companies are actively pursuing biosimilar approvals to offer alternative treatments. For example, in June 2023, a biosimilar to Xolair, known as YF-307, developed by biosimilar drug maker Sandoz, received a positive recommendation from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) [7]. This suggests that biosimilar competition could emerge, potentially impacting pricing and market access [7].
What is the Clinical Data Supporting Xolair's Use?
Xolair's efficacy and safety have been established through numerous clinical trials. For allergic asthma, pivotal studies demonstrated Xolair's ability to reduce exacerbation rates and improve lung function in patients inadequately controlled on standard therapies [2]. For chronic urticaria, clinical trials showed significant improvements in itch and hives severity with Xolair treatment compared to placebo [4].
What Are the Potential Side Effects of Xolair?
Common side effects reported in clinical trials for Xolair include injection site reactions, viral infections, and headaches [2][4]. A more serious, though rare, risk associated with Xolair is anaphylaxis, which can occur even after repeated doses [2][4]. Patients are advised to seek immediate medical attention if they experience symptoms of anaphylaxis, such as difficulty breathing, wheezing, dizziness, or rash [2][4].
Sources:
[1] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/xolair-omalizumab-drug-safety-communication-information-about-risk-anaphylaxis
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125206s033lbl.pdf
[3] https://www.xolair.com/hcp/allergic-asthma.html
[4] https://www.fda.gov/drugs/drug-approvals/drug-approvals-november-2016
[5] https://drugpatentwatch.com/en/drug/Xolair
[6] https://drugpatentwatch.com/en/drug/Xolair/patent
[7] https://www.sandoz.com/news/media-releases/sandoz-announces-positive-chmp-opinion-ysp-307-biosimilar-omalizumab